DR info

Clinical trials : 15 / Drugs : 48 - (DrugBank : 18) / Drug target genes : 31 - Drug target pathways : 65

Congenital nephrogenic diabetes insipidus and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)

ID	Diseases (Sorted by score)	Score
225	Congenital nephrogenic diabetes insipidus	-
86	Pulmonary arterial hypertension	23.435
13	Multiple sclerosis/Neuromyelitis optica	19.633
115	Hereditary periodic paralysis	13.000
154	Epilepsy with continuous spikes and waves during slow sleep	13.000
114	Non-dystrophic myotonia syndrome	10.954
230	Alveolar hypoventilation syndrome	10.954
155	Acquired aphasia with convulsive disorder	8.936
299	Cystic fibrosis	8.672
90	Retinitis pigmentosa	8.667
6	Parkinson disease	6.143
97	Ulcerative colitis	3.800
67	Polycystic kidney disease	3.368
51	Scleroderma	3.202
113	Muscular dystrophy	2.929
58	Hypertrophic cardiomyopathy	2.416
46	Malignant rheumatoid arthritis	2.387
337	Homocystinuria	2.000
282	Congenital dyserythropoietic anemia	2.000
77	Growth hormone secreting pituitary adenoma	2.000
294	Congenital diaphragmatic hernia	1.920
222	Primary nephrotic syndrome	1.672
75	Cushing disease	1.665
88	Chronic thromboembolic pulmonary hypertension	1.600
65	Primary immunodeficiency	1.520
210	Single Ventricle	1.484
49	Systemic lupus erythematosus	1.453
158	Tuberous sclerosis	1.429
96	Crohn disease	1.371
2	Amyotrophic lateral sclerosis	1.367
271	Ankylosing spondylitis	1.341
21	Mitochondrial disease	1.277
298	Hereditary pancreatitis	1.226
206	Fragile X syndrome	1.219
301	Macular dystrophy	1.200
84	Sarcoidosis	1.087
251	Urea cycle disorder	1.067
72	Pituitary ADH secretion disorder	1.067
71	Idiopathic osteonecrosis of the femoral head	1.067
265	Lipodystrophy	1.067